“…Through its binding to RAR , TAC-101 interferes with the binding of AP-1 to DNA, and inhibits production of urokinase plasminogen activator (uPA) and matrix metalloproteinase 9 (MMP-9). In several studies, TAC-101 has shown inhibition of tumor growth and hepatic metastases in several cancers including colorectal, gastric, pancreatic, and lung cancer and inhibits angiogenesis via down regulation of vascular endothelial growth factor (VEGF) mRNA and protein in a colon cancer model (Hashimoto et al 1996;Murakami et al 1998a, b;Oikawa 1998;Fujimoto et al 1999;Miyaguchi et al 2001;Oikawa et al 2001;Rizvi et al 2002;Lee et al 2003;Miyagawa et al 2003;Sano et al 2003;Satake et al 2003;Yoshimura et al 2003;Minagawa et al 2004;Shudo et al 2004;Suzuki et al 2004;Sako et al 2005). In a gastric cancer animal model, TAC-101 was shown to decrease cellinduced angiogenesis (decreased microvessel density and new blood vessel formation).…”